PriceTargets.com logo

Evaxion Biotech A/S - EVAX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 596.20%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.58 As of 12/3/2024 12:36 PM ET
▲ +0.04 (2.60%)

This chart shows the closing price for EVAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evaxion Biotech A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVAX

Analyst Price Target is $11.00
▲ +596.20% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evaxion Biotech A/S in the last 3 months. The average price target is $11.00, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 596.20% upside from the last price of $1.58.

This chart shows the closing price for EVAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Evaxion Biotech A/S. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
9/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
9/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
8/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
4/2/2024LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$8.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
2/12/2024HC WainwrightInitiated CoverageBuy$14.00
12/21/2023LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral
3/31/2023Lake Street CapitalLower TargetBuy$180.00 ➝ $70.00
11/17/2022OppenheimerLower TargetOutperform$160.00 ➝ $110.00
7/18/2022OppenheimerReiterated RatingOutperform$160.00
7/30/2021Lake Street CapitalInitiated CoverageBuy$210.00
6/23/2021LADENBURG THALM/SH SHReiterated RatingBuyC$230.00
3/2/2021OppenheimerInitiated CoverageOutperform$180.00
3/2/2021LADENBURG THALM/SH SHInitiated CoverageBuy
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/7/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/5/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
10/4/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Evaxion Biotech A/S logo
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Read More

Today's Range

Now: $1.58
Low: $1.56
High: $1.59

50 Day Range

MA: $2.45
Low: $1.37
High: $3.11

52 Week Range

Now: $1.58
Low: $1.28
High: $13.61

Volume

2,921 shs

Average Volume

213,001 shs

Market Capitalization

$9.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Evaxion Biotech A/S?

The following sell-side analysts have issued stock ratings on Evaxion Biotech A/S in the last twelve months: HC Wainwright, and LADENBURG THALM/SH SH.
View the latest analyst ratings for EVAX.

What is the current price target for Evaxion Biotech A/S?

0 Wall Street analysts have set twelve-month price targets for Evaxion Biotech A/S in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 596.2%. HC Wainwright has the highest price target set, predicting EVAX will reach $14.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $8.00 for Evaxion Biotech A/S in the next year.
View the latest price targets for EVAX.

What is the current consensus analyst rating for Evaxion Biotech A/S?

Evaxion Biotech A/S currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVAX will outperform the market and that investors should add to their positions of Evaxion Biotech A/S.
View the latest ratings for EVAX.

What other companies compete with Evaxion Biotech A/S?

Other companies that are similar to Evaxion Biotech A/S include OKYO Pharma, Pluri, MiNK Therapeutics, Calidi Biotherapeutics and SAB Biotherapeutics. Learn More about companies similar to Evaxion Biotech A/S.

How do I contact Evaxion Biotech A/S's investor relations team?

Evaxion Biotech A/S's physical mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The company's listed phone number is 45-5353-1850 and its investor relations email address is [email protected]. The official website for Evaxion Biotech A/S is www.evaxion-biotech.com. Learn More about contacing Evaxion Biotech A/S investor relations.